Evidence map›Paper›PMID 41307991›Full record

ArticleCell reports2025

Potentiation of noncanonical NF-κB signaling and marginal zone B cell expansion by CARD11-mediated regulation of p100 processing.

Anushka Ghosh, Tyler A Jones, Sophie Mackinnon, Shelby M Hutcherson, Julia M Tritapoe, Piyusha Mongia, Neha Shah, Emma M Mehlhop, Nicole M Carter, Joel L Pomerantz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anushka GhoshDepartments of Biological Chemistry and Physiology, Pharmacology, and Therapeutics and Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tyler A JonesDepartments of Biological Chemistry and Physiology, Pharmacology, and Therapeutics and Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sophie MackinnonDepartments of Biological Chemistry and Physiology, Pharmacology, and Therapeutics and Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Shelby M HutchersonDepartments of Biological Chemistry and Physiology, Pharmacology, and Therapeutics and Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Julia M TritapoeDepartments of Biological Chemistry and Physiology, Pharmacology, and Therapeutics and Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Piyusha MongiaDepartments of Biological Chemistry and Physiology, Pharmacology, and Therapeutics and Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Neha ShahDepartments of Biological Chemistry and Physiology, Pharmacology, and Therapeutics and Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Emma M MehlhopDepartments of Biological Chemistry and Physiology, Pharmacology, and Therapeutics and Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Nicole M CarterDepartments of Biological Chemistry and Physiology, Pharmacology, and Therapeutics and Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Joel L PomerantzDepartments of Biological Chemistry and Physiology, Pharmacology, and Therapeutics and Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: joel.pomerantz@jhmi.edu.

Funding

Mechanisms of Control of Lymphocyte Activation and Proliferation by a Critical Signaling IntegratorR01AI148143 · NIAID · JOHNS HOPKINS UNIVERSITY · PI POMERANTZ, JOEL L · 2020 to 2024
$2.3M
NIAID NIH HHS R01 AI148143
6 · The paper itself

Abstract

The signaling scaffold CARD11 is critical for adaptive immunity and antigen receptor signaling to canonical nuclear factor κB (NF-κB), mTOR, JNK, and AKT. Oncogenic gain-of-function (GoF) CARD11 mutants, implicated in a variety of lymphomas, bypass regulation and signal constitutively. In mice expressing the lymphoma-associated mutation CARD11 C49Y, we observe B cell expansion that is most impressive for marginal zone (MZ) B cells. CARD11

Indexed as

B-LymphocytesCARD Signaling Adaptor ProteinsGuanylate CyclaseNF-kappa BNF-kappa B p52 SubunitSignal TransductionAnimalsB-Cell Activating FactorCell ProliferationHumansMiceMice, Inbred C57BLB-Cell Activating FactorCARD11 protein, humanCard11 protein, mouseCARD Signaling Adaptor ProteinsGuanylate CyclaseNF-kappa BNF-kappa B p52 Subunitantigen receptor signalingB cell homeostasisBENTAcanonical NF-κBCARD11CBM complexCP: cancerCP: immunologydiffuse large B cell lymphomalymphomanoncanonical NF-κB

Identifiers

PMID41307991
PMCPMC12818902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.